Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases by A.A. de Jesus et al.
Distinct interferon signatures and cytokine
patterns define additional systemic
autoinflammatory diseases
Adriana A. de Jesus, … , Scott W. Canna, Raphaela
Goldbach-Mansky
J Clin Invest. 2020. https://doi.org/10.1172/JCI129301.
  
Undifferentiated systemic autoinflammatory diseases (USAIDs) present diagnostic and
therapeutic challenges. Chronic interferon (IFN) signaling and cytokine dysregulation may
identify diseases with available targeted treatments.
Sixty-six consecutively referred USAID patients underwent underwent screening for the
presence of an interferon signature using a standardized type-I IFN-response-gene score
(IRG-S), cytokine profiling, and genetic evaluation by next-generation sequencing.
Thirty-six USAID patients (55%) had elevated IRG-S. Neutrophilic panniculitis (40% vs.
0%), basal ganglia calcifications (46% vs. 0%), interstitial lung disease (47% vs. 5%), and
myositis (60% vs. 10%) were more prevalent in patients with elevated IRG-S. Moderate IRG-
S elevation and highly elevated serum IL-18 distinguished 8 patients with pulmonary
alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS). Among
patients with panniculitis and progressive cytopenias, 2 patients were compound
heterozygous for potentially novel LRBA mutations, 4 patients harbored potentially novel
splice variants in IKBKG (which encodes NF-kB essential modulator [NEMO]), and 6
patients had de novo frameshift mutations in SAMD9L. Of additional 12 patients with
elevated IRG-S and CANDLE-, SAVI- or Aicardi-Goutières syndrome–like (AGS-like)
phenotypes, 5 patients carried mutations in either SAMHD1, TREX1, PSMB8, or PSMG2.
Two patients had anti-MDA5 autoantibody–positive juvenile dermatomyositis, and […]
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onset in infancy (SAVI), and another by additive loss-of-function 
mutations in proteasome genes causing the proteasome-associat-
ed autoinflammatory syndromes (PRAAS) (also, chronic atypical 
neutrophilic dermatosis with lipodystrophy and elevated tempera-
tures [CANDLE]), presented with chronically elevated interferon 
(IFN) signatures, suggesting a pathogenic role for type-I IFN in 
autoinflammatory diseases (2, 3). Type-I IFN was first discovered 
as a soluble antiviral factor over 50 years ago, and a role in sterile 
inflammation was proposed in patients with systemic lupus ery-
thematosus (4). However, the discovery of genetic mutations that 
cause the autoinflammatory type-I interferonopathies CANDLE 
(2, 5), SAVI (3, 6–8), and Aicardi-Goutières syndrome (AGS) (9, 10) 
have shed light on pathomechanisms that drive chronic IFN sig-
naling, and recent studies blocking IFN signaling validate a critical 
role for type-I IFNs (11). AGS-causing loss-of-function mutations 
in nucleases impair self–nucleic acid homeostasis, SAVI-causing 
Introduction
The discovery of Mendelian defects that cause immune-dysregu-
latory and autoinflammatory diseases rapidly expanded our abili-
ty to diagnose pediatric patients with systemic sterile inflamma-
tion and provided insights into pathogenic mechanisms that cause 
organ inflammation and damage. Furthermore, pathogenesis 
and treatment studies in autoinflammatory diseases converge on 
confirming a key role of proinflammatory cytokines in amplifying 
abnormal immune responses, which have become effective tar-
gets for treatments (1).
Mutations in IL-1–activating inflammasomes (including 
NLRP3 and pyrin) and their remarkable response to IL-1–inhibit-
ing therapies suggest a central role for IL-1 in their pathogenesis 
(1). More recently, 2 diseases with systemic inflammation, one 
caused by gain-of-function mutations in the viral sensor STING1/ 
TMEM173 (STING) causing STING-associated vasculopathy with 
BACKGROUND. Undifferentiated systemic autoinflammatory diseases (USAIDs) present diagnostic and therapeutic 
challenges. Chronic interferon (IFN) signaling and cytokine dysregulation may identify diseases with available targeted 
treatments.
METHODS. Sixty-six consecutively referred USAID patients underwent underwent screening for the presence of an interferon 
signature using a standardized type-I IFN-response-gene score (IRG-S), cytokine profiling, and genetic evaluation by next-
generation sequencing.
RESULTS. Thirty-six USAID patients (55%) had elevated IRG-S. Neutrophilic panniculitis (40% vs. 0%), basal ganglia 
calcifications (46% vs. 0%), interstitial lung disease (47% vs. 5%), and myositis (60% vs. 10%) were more prevalent in 
patients with elevated IRG-S. Moderate IRG-S elevation and highly elevated serum IL-18 distinguished 8 patients with 
pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS). Among patients with 
panniculitis and progressive cytopenias, 2 patients were compound heterozygous for potentially novel LRBA mutations, 
4 patients harbored potentially novel splice variants in IKBKG (which encodes NF-κB essential modulator [NEMO]), and 6 
patients had de novo frameshift mutations in SAMD9L. Of additional 12 patients with elevated IRG-S and CANDLE-, SAVI- or 
Aicardi-Goutières syndrome–like (AGS-like) phenotypes, 5 patients carried mutations in either SAMHD1, TREX1, PSMB8, or 
PSMG2. Two patients had anti-MDA5 autoantibody–positive juvenile dermatomyositis, and 7 could not be classified. Patients 
with LRBA, IKBKG, and SAMD9L mutations showed a pattern of IRG elevation that suggests prominent NF-κB activation 
different from the canonical interferonopathies CANDLE, SAVI, and AGS.
CONCLUSIONS. In patients with elevated IRG-S, we identified characteristic clinical features and 3 additional 
autoinflammatory diseases: IL-18–mediated PAP and recurrent MAS (IL-18PAP-MAS), NEMO deleted exon 5–
autoinflammatory syndrome (NEMO-NDAS), and SAMD9L-associated autoinflammatory disease (SAMD9L-SAAD). The IRG-S 
expands the diagnostic armamentarium in evaluating USAIDs and points to different pathways regulating IRG expression.
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synergy with IL-12 in promoting the production of the type-II IFN, 
IFN-γ (19), which emerges as the critical factor in leading to the 
hyperinflammatory state of MAS (14).
Emerging data from interventional studies targeting the 
type-I IFN and IL-18/type-II IFN pathways have shown benefit 
in patients with these diseases and treatment also might benefit 
patients who currently have no genetic diagnosis but evidence of 
immune dysregulation in the respective inflammatory pathways. 
Patients with chronically elevated IFN signatures may clinically 
respond to treatments that block type-I IFN signaling (11). Like-
wise, patients with high serum IL-18 levels and an MAS predisposi-
tion might respond to treatments that target IL-18 (20) and/or the 
type-II IFN, IFN-γ (21).
Comprehensive clinical phenotyping of undifferentiated sys-
temic autoinflammatory disease (USAID) patients and screening 
for an IFN signature by using a standardized type-I IFN response 
gene score (IRG-S), a targeted cytokine profile, and by genomic 
evaluation, led to the identification of 3 additional autoinflamma-
tory diseases, IL-18–associated pulmonary alveolar proteinosis 
(PAP) and MAS syndrome (IL-18PAP-MAS), NEMO deleted exon 
5–autoinflammatory syndrome (NEMO-NDAS), and SAMD9L- 
associated autoinflammatory disease (SAMD9L-SAAD). The pref-
gain-of-function mutations in STING1/TMEM173 lead to chronic 
predominantly IFN-β production, and PRAAS-causing loss-of-
function mutations in proteasome genes cause an elevated IFN 
signature that is independent of nucleic acids and viral sensor 
activation and points to additional intracellular mechanisms that 
trigger an IFN signature.
A link between autoinflammation and type-II IFN (IFN-γ) 
was recently established via the discovery of gain-of-function 
mutations in NLRC4 (12, 13). Patients demonstrate chronically 
and extremely high levels of serum IL-18, as well as evidence for 
IFN-γ activity during flares (14). Highly elevated serum IL-18 lev-
els emerged as risk factors for developing macrophage activation 
syndrome (MAS) and have been associated with the development 
of MAS in systemic juvenile idiopathic arthritis and adult-onset 
Still’s disease (15, 16). The disease-causing NLRC4 mutations 
have associated the NLRC4 inflammasome but not the other 
inflammasomes with very high IL-18 activation (15). Mutations in 
XIAP (17) and CDC42 (18) are other monogenic autoinflammatory 
syndromes with high IL-18 levels that predispose to the develop-
ment of MAS, thus providing genetically defined disease models 
to study the role of IL-18 in MAS. The presence of free IL-18 in 
these patients with ultrahigh serum IL-18 levels may modify the 
Figure 1. Study overview, patient allocation and diagnosis. All patients were screened for elevation of an IFN-response-gene score (IRG-S) except for 1 
patient (G4-P5), who was diagnosed postmortem based on WES with SAMD9L-SAAD. Patients were characterized based on presence or absence of an 
elevated IRG-S. All patients underwent clinical phenotyping, cytokine analyses, and genetic testing (WES/WGS or Sanger sequencing). Negative–IRG-S 
patients were clinically grouped (see supplement). Positive–IRG-S patients were grouped as CANDLE-like, SAVI-like, and AGS-like disease. Cytokine analyses 
and genetic analyses allowed for the characterization of patients with 3 additional diseases: IL-18PAP-MAS, NEMO-NDAS, and SAMD9L-SAAD (in red); and 
2 patients had LRBA deficiency. Three patients had CANDLE, 1 AGS5, and 2 had anti-MDA5 autoantibody positive juvenile dermatomyositis. Seven patients 
with an elevated IRG-S and 7 patients with negative IRG-S could not be further classified. *No monogenic candidate gene. **Negative–IRG-S patients were 
classified as CRMO/CRMO-like (n = 5), CAPS/CAPS-like (n = 4), periodic fever syndrome (n = 6), Still’s-like disease and MAS (n = 3); 7 patients could not be 
classified. ***Two patients (G1-P5 and G4-P6) only had one sample, 1 patient (G4-P3) had a bone marrow transplant (BMT) and no pre-BMT sample avail-
able, and 1 patient (G1-P3) had 3 negative samples.
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of patients with an elevated IRG-S during disease flares (Table 1 
and Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI129301DS1). Clinical 
and laboratory features varied in patients with and without ele-
vated IRG-S and a significantly earlier disease onset was observed 
in patients with elevated IRG-S (Figure 2, B–G, Table 1, and Sup-
plemental Table 1). Panniculitis was present in 22 patients (54%) 
included in disease groups with an elevated IRG-S, compared with 
no patient with a normal IRG-S (P < 0.0001). Similarly, basal gan-
glia calcifications were present in 12 out of 26 patients (46%) with 
elevated IRG-S who had either CTs or MRIs compared with none 
of 14 patients with normal IRG-S (P < 0.01). Other clinical features 
that were more frequent in patients with elevated IRG-S included 
interstitial lung disease (47% vs. 5% in patients with normal IRG-S), 
myositis (60% vs. 10% with normal IRG-S), arterial hypertension 
(30% vs. 4% with normal IRG-S), and liver enzyme elevation (61% 
vs. 12% with normal IRG-S) (Table 1).
erential elevation of IFN-response genes (IRGs) with STAT-1 and 
NF-κB binding sites in patients with NEMO-NDAS, LPS-responsive 
beige-like anchor protein (LRBA) deficiency, and SAMD9L-SAAD 
suggests a prominent role for both NF-κB and IFN signaling, which 
is distinct from CANDLE, SAVI, and AGS.
Results
Screening by using a validated IFN response gene score (IRG-S) identi-
fies distinct clinical features in patients with elevated IRG-S compared 
with patients with normal IRG-S. IRG expression is low in healthy 
controls and untreated patients with the IL-1–mediated disease, 
neonatal-onset multisystem inflammatory disease (NOMID), and 
elevated in patients with PRAAS/CANDLE and SAVI. Of 65 patients 
tested for IRG-S elevation (see workflow in Figure 1), 36 (55%) had 
elevated IRG-S with an active disease flare and 29 patients were 
negative (Figure 2A). Four of the 29 patients with a normal IRG-S at 
the time of testing were later included in one of the disease groups 
Figure 2. Shared clinical features and different cytokine profiles in patients with and without elevated IFN scores. (A) An elevated IFN-response gene 
score (IRG-S) distinguishes 36 patients during active disease from 29 patients who had normal IFN scores during bouts of active disease. Nonparametric 
(Kruskal-Wallis) test was used for multiple comparisons of IFN or Non-IFN groups with healthy controls (HC) or with CANDLE and SAVI patients combined. 
Depicted in the graph are the statistical significances (Kruskal-Wallis test) from the comparisons of each group (NOMID, IFN, and Non-IFN groups) with 
CANDLE and SAVI patients combined. Each individual patient is represented by a different symbol shape. ****P < 0.0001; NS, not significant. Bars and 
error lines indicate median and interquartile range, respectively; dotted line indicates the 28-gene IFN score cutoff (48.9) previously described (34). Multiple 
comparisons of each group (NOMID, CANDLE, and SAVI combined; IFN and Non-IFN) with HC (not depicted): NOMID P = 0.5004, CANDLE + SAVI P < 0.0001, 
IFN P < 0.0001, Non-IFN P = 0.2986. For HC, NOMID, and non-IFN groups, the same symbol is used for different individuals, as only 1 sample per patient is 
included. For CANDLE, SAVI, and IFN groups, each patient is represented by a different symbol. (B–G) Characteristic clinical features that were present only 
in patients with elevated IFN scores included panniculitis with lipoatrophy (B), neutrophilic vasculitis (C), erythematous macular rash (D), Gottron’s papules 
(E), interstitial lung disease (F), and basal ganglia calcifications (G). Four patients (per groups defined in Table 2; Group 1 – patient 3 [G1-P3] and G1-P5, G4-P2 
and G4-P5) had negative IRG-S but were later added to the respective groups when a clinical or genetic diagnosis was made (not depicted).
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The IRG-S elevation was thought to be associated with active dis-
ease, although absence of infection could not always be excluded 
as a contributing factor to the increased IRG-S.
Of the 41 patients in the disease groups with elevated IRG-S, 
18 were diagnosed with additional diseases based on clinical 
phenotype, cytokine and/or genetic analyses, and are described 
in groups 1 to 4 (G1–G4). Eight patients with PAP and recurrent 
MAS were grouped into G1. Twelve patients with CANDLE-like 
features had relatively lower IRG-S with disease flares than 
patients with CANDLE and were later genetically classified with 
distinct diseases: LRBA deficiency (G2, n = 2), NEMO-NDAS (G3, 
n = 4), and SAMD9L-SAAD (G4, n = 6). Several patients with high 
IRG-S resembled AGS (G5, n = 4) and one of them had a known 
mutation in SAMHD1. Two patients with high IRG-S, interstitial 
lung disease, soft tissue calcifications, and myositis had elevated 
anti-MDA5 autoantibodies, consistent with anti-MDA5 autoanti-
body–positive juvenile dermatomyositis (JDM) (G6, n = 2). Of the 
On laboratory evaluation (Supplemental Table 2), lymphope-
nia (with low B cell and NK cell counts) and thrombocytopenia 
were present in 24%–31% of patients with elevated IRG-S com-
pared with none with normal IRG-S; patients with high IRG-S were 
more frequently anemic (36% vs. 8%). Antinuclear antibodies 
were present in patients with and without an elevated IRG-S (33% 
vs. 11%, P = nonsignificant) but were more prevalent in patients 
with an elevated IRG-S; anti-dsDNA antibodies and anti-neutro-
phil antibodies (anti-PR3 and anti-MPO) were low positive in 1 or 2 
patients with an elevated IRG-S each. In contrast, autoantibodies 
against endothelial lipoproteins (anti-cardiolipin, lupus anticoag-
ulant) were equally positive in patients with and without elevated 
IRG-S. Serum IgA and IgM levels were higher in patients with ele-
vated IRG-S (Supplemental Table 2).
Mortality within the study period was high in patients with 
positive IRG-S: 8 out of 41 (19.5%) expired within the study period 
(2014 to 2018); all patients with normal IRG-S are alive (Table 1). 
Table 1. Clinical features of genetically defined type-I interferonopathies and noninterferonopathies
Clinical Feature With IFN signature affected/no. 
patients evaluated (%) n = 41A
Without IFN signature affected/no. 
patients evaluated (%) n = 25
Fisher’s exact test P value
Demographics Age of disease onset (median [IQR]), 
monthsB
6 (0–15) 24 (1.5–57) 0.009G
Age of disease onset < 2 yr 31/41 (75) 12/25 (48) 0.033
Female 24/41 (58) 11/25 (44) NS
White 21/41 (51) 21/25 (84) 0.009
MortalityC 8/41 (19.5) 0/25 (0) 0.020
Skin Any rash 37/39 17/25 0.010
Panniculitis with or without 
lipodystrophy
22/41 (54) 0/25 (0) <0.0001
Pustulosis 2/41 (5) 3/25 (12) NS
Pyoderma gangrenosum 1/41 (2.4) 1/25 (4) NS
Neurologic Basal ganglia calcifications 12/26 (46) 0/14 (0) 0.003
Demyelinating diseaseD 7/25 (28) 1/14 (7) NS
Aseptic meningitisE 3/28 (11) 1/22 (4.5) NS
Pulmonary Interstitial lung disease with or without 
clubbingF
18/38 (47) 1/19 (5.3) 0.002
Musculoskeletal MyositisH 21/35 (60) 2/19 (10) 0.0005
Aseptic osteomyelitis 1/40 (2.5) 6/19 (32) 0.010
Vascular Skin vasculitis 10/40 (25) 2/25 (8) NS
Stroke 2/37 (5.4) 1/25 (4) NS
Arterial hypertension 10/33 (30) 1/25 (4) 0.016
Vascular calcification 5/33 (15) 0/19 (0) NS
Liver disease Transaminitis 23/38 (61) 3/25 (12) 0.0002
Abnormal liver biopsyI 7/38 (16) 1/25 (4) NS
Other MAS 11/39 (28) 2/25 (8) 0.062
AFor clinical phenotyping, 4 patients (G1-P3, G1-P5, G4-P3, and G4-P6) were negative and 1 patient (G4-P5) did not have an IFN-response-gene score 
(IRG-S) tested but were later added to the respective groups when clinical or genetic diagnosis was made. The final number of subjects in the group 
of patients with a diagnosis related to a “positive” IRG-S (with IFN signature) was 41, and 25 patients were listed with “negative” IRG-S (without IFN 
signature). BTwo patients in this group had disease onset above 18 years old and were excluded from the analysis. COne patient with SAMD9L-associated 
autoinflammatory disease (SAMD9L-SAAD) was diagnosed postmortem (G4-P5). DPatients with magnetic resonance imaging (MRI). EPatients with lumbar 
puncture. FPatients with chest computed tomography. GUnpaired t test was performed. HMyositis was defined as elevated creatine kinase or aldolase and/
or abnormal muscle MRI. IUndifferentiated interferonopathy (UIFN) group: histiocyte infiltration (n = 1) (G1-P3); granulomatous hepatitis (n = 2) (G2-P1 and 
G3-P1); autoimmune hepatitis with liver fibrosis (n = 1) (G2-P2); nodular regenerative hyperplasia (n = 1) (G5-P3); ballooning and necrosis of hepatocytes 
(n = 2) (G6-P1 and G6-P2); and periportal fibrosis (n = 1) (G6-P1). Noninterferonopathy (Non-IFN) group: liver fibrosis and vanishing bile duct disease (n = 1) 
(GN5-P3). Features with P values in bold were significantly different between patients with and without IFN signatures.
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remaining patients in the disease groups with positive IRG-S, 3 had 
mutation-positive CANDLE and 3 had CANDLE-like features and 
were grouped in group 7 (G7, n = 6). Of the 3 CANDLE patients, 
1 had a known mutation (n = 1), and 1 had a potentially novel 
mutation (n = 1) in the CANDLE-causing gene PSMB8. The third 
patient was compound heterozygous for mutations in a potentially 
novel CANDLE-causing gene, PSMG2 (n = 1). Two patients with 
SAVI-like features did not have disease-causing mutations and are 
described in G8 (SAVI-like)(n = 2) (see Supplemental Methods for 
definition of disease categories, Supplemental Methods A). Seven 
patients, each with clinical features unlike any other patient, could 
not be grouped or classified (G9, n = 7).
We assessed 48 cytokines in 53 patients with available serum 
samples (Supplemental Figure 1). The median IP-10 levels were 
significantly higher in patients with an elevated IRG-S (n = 20) 
compared with those with a normal IRG-S (n = 25) (7,369 [range 
404.1–25,884] vs. 622.1 [191.4–3,185] pg/mL, P < 0.0001). Other 
cytokines that were significantly elevated include MIG/CXCL9 
(2,890 [range 441.9–43,205] vs. 737.5 [83.4–1,272] pg/mL, P = 
0.0001), SCF/KITLG (38.9 [4.3–209.8] vs. 20.9 [3.5–107.2] pg/
mL, P = 0.0156), GROα/CXCL1 (251.6 [74.9–1,696] vs. 161.7 
[24.9–314.8] pg/mL, P = 0.0043), and TRAIL (94.8 [18.1–633.3] 
vs. 47.9 [10.7–290.0] pg/mL, P = 0.0277).
Highly elevated serum IL-18 levels, PAP, and recurrent MAS char-
acterize a defined clinical syndrome. Eight patients with a history of 
recurrent MAS, PAP, and nail clubbing (Figure 3, A–C) had ultra-
high elevations of serum IL-18 levels (Figure 3, D and E). Three 
were repeatedly tested for the entire cytokine panel and had sig-
nificantly increased expression of a 12-cytokine signature nearly 
identical to that seen in patients with an NLRC4 gain-of-function 
mutation and recurrent MAS (NLRC4-MAS), which includes 
hematopoietic growth factors/cytokines like M-CSF, SCF, and 
IL-3 (12) (Figure 3D). However, whole-exome sequencing (WES) 
did not reveal definitive candidate mutations and no patient had 
NLRC4 mutations. The distinct clinical presentation with PAP, the 
very high IL-18 levels (Figure 3E), an IL-18/CXCL9 ratio similar to 
patients with NLRC4-MAS (14) (Figure 3F), and a cytokine signa-
ture previously associated with recurrent MAS clinically suggest 
a previously unrecognized disease, that is subsequently referred 
to as IL-18–associated PAP and MAS syndrome (IL-18PAP-MAS). 
These patients are combined in G1. Of the 8 patients, 7 had active 
disease at the time of assessment and 6 had an elevated IRG-S 
with active disease, although elevations were significantly lower 
than in CANDLE and SAVI (P = 0.0002 and P = 0.0003, respec-
tively) (Figure 4A). In 1 patient with inactive disease and a normal 
C-reactive protein (CRP) at the time of blood draw, serum IL-18 
levels had dropped from 430,423 pg/mL during active disease to 
2,506 pg/mL (normal <500 pg/mL) and the IRG-S was normal. 
This patient was included in G1 due to the clinical phenotype of 
IL-18PAP-MAS and the ultrahigh IL-18 levels at the time of active 
disease. Supplemental Table 3 includes the clinical features and 
treatments for the IL-18PAP-MAS group.
Genetic analyses of 12 patients with CANDLE-like clinical pheno-
types including panniculitis, but also progressive B cell lymphopenia, 
and low/intermediate IRG-S revealed potentially novel mutations in 
LRBA, potentially novel splice variants in IKBKG/NEMO, and trun-
cating mutations in SAMD9L. Twelve patients with CANDLE-like 
phenotypes who were negative for known CANDLE-causing muta-
tions had low/intermediate IRG-S and all developed progressive 
cytopenias. WES identified 2 patients with potentially novel or very 
Table 2. Diagnoses of patients with elevated type-1 IFN score (IRG-S), including genetic and immune evaluation
Disease 
group
Number of 
patients in 
group  
(n = 41)
Disease name Number of 
patients with 
monogenic 
disease-causing 
mutation
Presumed genetic mechanism Possible candidate/modifying 
genes
Diagnostic approach to a clinical 
diagnosis E
Group 1 n = 8 IL-18 PAP-MAS n = 0A poly/oligogenic none/possible modifying genes Clinical phenotype and cytokine 
analysis (high IL-18) 
Group 2 n = 2 LRBA deficiency n = 2B LRBA compound heterozygous, 
recessive
monogenic/modifying genes Genetic testing (WES)
Group 3 n = 4 NEMO-NDAS n = 4 IKBKG encoding NEMO, novel splice 
site mutations, X-linked
monogenic/none Genetic testing (WGS)
Group 4 n = 6 SAMD9L-SAAD n = 6C SAMD9L, de novo frameshift 
mutations, autosomal dominant
monogenic/none Genetic testing (WES), trio analysis
Group 5 n = 4 AGS/AGS-like n = 1 SAMHD1, recessive 1 candidate gene/NA Genetic testing (WGS)
Group 6 n = 2 MYOSITIS plus positive  
anti-MDA5 autoantibody
n = 0 not known none/possible modifying genes Clinical phenotype and 
autoantibody testing
Group 7 n = 6 CANDLE/CANDLE-like with 
panniculitis
n = 4D PSMB8 recessive (n = 2); PSMG2 
recessive (n = 1); TREX1 de novo, 
somatic (n = 1)
2 candidate genes/NA Genetic testing (WES), trio analysis
Group 8 n = 2 SAVI-like n = 0 not known none/no modifying genes Clinical phenotyping
Group 9 n = 7 Miscellaneous n = 1 variable, not one disease possible candidates/NA Clinical phenotyping
AOne patient was diagnosed with myeloid leukemia after treatment for MAS that included etoposide. BBoth patients have modifying genes that may 
influence their phenotype. COne patient was included postmortem because of a disease-causing SAMD9L mutation that was identical to that in 2 other 
patients. DThree patients have potentially novel proteasome mutations and have CANDLE/PRAAS, and 1 patient had a known PSMB8 mutation, p.T75M. 
ESee Supplemental Table 7 for best-candidate genes.
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rare compound heterozygous LRBA mutations (22). One of the 
LRBA-deficiency patients (G2-P2) had severe lipoatrophy, hepato-
megaly, and type 2 insulin-resistant diabetes (DM type 2). A de novo 
mutation in IRS-1 (c.3632T>G; p.L1211R), encoding the insulin 
receptor substrate 1 previously associated with DM type 2 (23, 24), 
may have contributed to this phenotype but was not formally eval-
uated. Upon leptin replacement, the patient’s profound DM type 2 
and hepatosplenomegaly resolved (25). The patient subsequently 
developed transverse myelitis and septic arthritis and underwent 
a bone marrow transplant. The other patient (G2-P1) had recurrent 
neutrophilic panniculitis in predominantly lower extremities and 
granulomatous hepatitis (Supplemental Table 4). Both patients 
were combined in G2 based on their biallelic LRBA mutations, 
reduced surface expression of CTLA4, and reduced number of reg-
ulatory T cells, consistent with previous findings in patients with 
LRBA deficiency (26) (data not shown).
One patient with lymphohistiocytic panniculitis and chorio-
retinitis (G3-P1) had conical teeth reminiscent of the ectodermal 
dysplasia found in NEMO deficiency syndrome, which prompt-
ed targeted sequencing of IKBKG (the causative gene in NEMO 
deficiency), the gamma subunit of the IκB kinase complex that 
regulates NF-κB activation. This patient, 2 other males, and 1 girl 
with panniculitis, progressive B cell lymphopenia, and hypogam-
maglobulinemia all had de novo splice-site variants that lead to 
deletion of exon 5 of IKBKG (G3-P1 to G3-P4) and are listed under 
G3 (Supplemental Table 4).
Genetic evaluation of 6 other patients revealed 3 tightly clus-
tered de novo frameshift mutations in SAMD9L. All patients were 
clinically diagnosed as CANDLE due to the prominent neutrophil-
ic panniculitis that was clinically and histologically indistinguish-
able from CANDLE. However, 4 patients also had early-onset, 
severe interstitial lung disease, a clinical feature that is not seen in 
CANDLE (Figure 4B). These patients had lower IRG-S in the con-
text of high CRPs than CANDLE patients and developed progres-
sive isolated B cell and NK cell cytopenias (Supplemental Table 4). 
One patient, who succumbed from respiratory failure at the age 
of 2 months, was included postmortem; she and 2 other patients 
had the identical de novo frameshift mutations in SAMD9L. Two 
Figure 3. Clinical features and cytokine dysregulation in patients with IL-18PAP-MAS (n = 8). (A) Nail clubbing. (B) Interstitial and alveolar lung disease. 
(C) Histologic features characteristic of pulmonary alveolar proteinosis (PAP). Original magnification, ×20. (D) Heatmap of 22 out of 48 analytes tested. 
The 12-cytokine signature includes SDF-1α/CXCL12, IFN-α2, MCP-3/CCL7, β-NGF, TRAIL, SCF, IL-16, IL-3, IL-18, IL-12p40, TNF-β/Ltα, and M-CSF. The 12-cyto-
kine signature upregulation tracks with ultrahigh IL-18 levels that are also seen in patients with recurrent macrophage activation syndrome (MAS) and 
gain-of-function mutations in NLRC4 (12). Two other patients with the 12-cytokine signature (*) had MAS but no pulmonary disease. (E) Serum IL-18 levels 
in patients with IL-18PAP-MAS and healthy and disease controls. HC, healthy controls; IL-18PAP-MAS, G1 patients with PAP and recurrent MAS (n = 8); 
NLRC4/MAS, patients with monogenic NLRC4-mediated MAS (n = 5); NOMID, neonatal-onset multisystem inflammatory disease (n = 8); SAVI, STING- 
associated vasculopathy with onset in infancy (n = 5); CANDLE, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (n 
= 8). (F) IL-18/CXCL9 ratio has previously been described to a cutoff of 2.3 (15), which is indicated with a gray horizontal line. IL-18PAP-MAS (n = 7); NLRC4/
MAS, patients with monogenic NLRC4-mediated MAS (n = 5). In E and F, nonparametric test (Kruskal-Wallis) was performed for multiple comparisons and 
all significant differences are shown. In E, populations in brackets share the same significance pattern. *P < 0.05; **P < 0.01; ****P < 0.0001.
The Journal of Clinical Investigation C L I N I C A L  M E D I C I N E
8 jci.org
previously unrecognized autoinflammatory disease, referred to as 
SAMD9L-SAAD (G4) (Figure 4, A–C, and Supplemental Table 4).
Potentially novel and known mutations in PRAAS/CANDLE- 
and AGS-causing genes characterize patients with high IRG-S 
and suggestive clinical features. Of 4 patients summarized in G5 
with neurologic disease manifestations, 2 had spastic quadri-
plegia and were wheelchair bound (G5-P2 and G5-P3); patient 
2 expired in the context of a presumed infection. One patient 
(G5-P1) who suffered a stroke at the age of 7 years had Moya-
Moya–like vasculopathy and was later found to have a previous-
ly described (27) homozygous SAMHD1 deletion. Patient G5-P3 
had spastic quadriplegia and peripheral vasculitis. Her father 
had a very high IRG-S and extensive basal ganglia calcifications 
patients with SAMD9L mutations (G4-P1 and G4-P4) had ele-
vated IRG-S. Of the other 3 patients tested, 2 (G4-P3 and G4-P5) 
had negative IRG-S and the third patient (G4-P2) had 4 samples 
tested, 3 with negative IRG-S, and 1 sample, obtained during a 
rhinovirus induced disease flare, had an elevated IRG-S. Two 
patients received bone marrow transplants: G4-P3 had received a 
sibling-matched bone marrow transplant at the age of 20 months, 
and a second patient (G4-P6) received an allogeneic bone marrow 
transplant at the age of 9 months.
The highly similar clinical presentation, progressive B cell 
lymphopenia, and genetic findings (frameshift mutations all with-
in 13 amino acids of each other, absent from public databases, and 
in a conserved protein domain) support their classification as a 
Figure 4. IFN score by disease group and clinical and genetic characteristics of SAMD9L-mediated autoinflammatory disease (SAMD9L-SAAD). (A) 
Twenty-eight–gene IFN scores by disease group. Nonparametric tests were used for multiple comparisons (Kruskal-Wallis) or individual group comparisons 
(Mann-Whitney). Each patient in groups 1 to 9 (G1 to G9) is represented by a different symbol shape. Depicted in the graph are the statistical significances 
(Kruskal-Wallis test) from the comparisons of each group (healthy controls [HC], NOMID, G1 to G4 combined, G5, G6, G7, G8, G9, and Non-IFN groups) 
with CANDLE and SAVI patients combined. *P = 0.0259; ****P < 0.0001; NS, not significant. Bars and error lines indicate median and interquartile range, 
respectively; dotted line indicates the 28-gene IFN score cutoff (48.9) previously described (34). For the control groups, HC and NOMID, the same symbol is 
used for different individuals, as only 1 sample per patient is included. For all other disease groups including CANDLE and SAVI, each patient is repre-
sented by a different symbol. (B) Clinical manifestations of SAMD9L-associated autoinflammatory disease (SAMD9L-SAAD) include nodular panniculitis 
and lipoatrophy (patient 1), interstitial lung disease (patient 6), and basal ganglia calcifications (patient 5). (C) SAMD9L domains and variant localization. 
SAM (blue), sterile α motif domain; AlbA/PPR (orange/yellow), DNA-binding domain; SIR2 (light blue), silent mating-type information regulator 2; P-loop 
NTPase (green), P-loop–containing NTP hydrolase; TPR (purple), tetratricopeptide repeat domain; OB (gray), oligonucleotide-binding fold domain; AA, 
amino acid; P1–P6, patient 1 to patient 6. Variants identified in SAMD9L-SAAD are in red, variants associated with ataxia-pancytopenia syndrome (APS) 
are in blue, and variants associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) are in green. Variants associated with either 
APS or MDS/AML are shown in purple.
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systemic inflammation but carried no obvious candidate muta-
tions (Table 2 and Supplemental Table 5).
G9 includes 7 patients with elevated IRG-S who could not be 
grouped on a clinical, immunological, or genetic basis (Supple-
mental Table 6).
Patients with negative–IFN-S can be grouped according to clin-
ical phenotype, genotype, and cytokine profile. The findings of the 
25 patients with negative IRG-S are described in Supplemental 
Table 7; these patients could be classified into 4 subgroups (GN1 
to GN-4). Five patients had chronic recurrent multifocal osteo-
myelitis (CRMO) (GN1, n = 5). GN1-P2 and GN1-P5 had exclusive 
jaw involvement and the others had long bone and spine involve-
ment; no unifying genetic hypothesis was found. Four patients had 
cryopyrin-associated periodic syndrome–like (CAPS-like) disease 
(GN2, n = 4). Interestingly, all had a rare variant of unknown sig-
nificance in NLRP3 that was inherited from a parent. All patients in 
GN2 had complete or partial responses to IL-1–blocking treatment, 
strengthening the concept that selected low-penetrance variants 
may predispose to the development of CAPS-like disease (31). No 
unifying genetic hypothesis was found for 6 patients with periodic 
fever syndromes (GN3, n = 6). Three patients with systemic juve-
nile idiopathic arthritis–like (sJIA-like) disease and MAS (GN4, n = 
3) had all high serum IL-18 levels between 9,878 pg/mL and 24,200 
pg/mL and IL-18/CXCL9 ratios greater than 1 that have previously 
been associated with increased risk for the development of MAS 
(15). Seven patients could not be grouped (GN5, n = 7).
Distinct gene expression patterns in 3 NF-κB–coregulated IRGs dis-
tinguish disease groups with both NF-κB and IFN signaling for poten-
during workup of “muscle weakness” and was subsequently 
included as a patient (G5-P4).
Two patients who suffered from digital ulcerations, interstitial 
lung disease, and myositis were initially thought to have an autoin-
flammatory disease, but the presence of anti-MDA5 autoantibod-
ies was consistent with a diagnosis of anti-MDA5 autoantibody–
positive JDM. No obvious candidate gene was identified, and 
these patients (G6-P1 and G6-P2) were grouped together in G6.
Six patients with CANDLE-like features, who had no cyto-
penias but high IRG-S, were included in G7. Of these, 3 had 
disease-causing CANDLE mutations (G7-P4 through G7-P6). 
Patient G7-P4 was homozygous for a known PSMB8 mutation 
(p.T75M). Patient G7-P5 was compound heterozygous for 2 poten-
tially novel PSMB8 mutations (p.S118P and p.Q55*) and patient 
G7-P6 harbored potentially novel compound heterozygous 
mutations in the proteasome assembly gene, PSMG2 (PAC2), 
that were recently confirmed to be pathogenic (28). Patient 
G7-P3 had severe localized panniculitis, localized lipoatrophy, 
and basal ganglia calcifications without white matter disease, 
and harbored a de novo somatic mutation (~26% allele fraction) 
in TREX1 that was previously associated with autosomal domi-
nant AGS1 as a germline mutation (29). Four G7 patients (G7-P3, 
G7-P4, G7-P5, and G7-P6) were treated with JAK inhibitors with 
partial or good responses. Patient G7-P4 died due to severe pul-
monary hypertension, which developed before initiation of JAK 
inhibitor treatment (30). Two siblings, G7-P1 and G7-P2, have no 
genetic diagnosis. G8 includes 2 patients with SAVI-like disease 
(G8-P1 and G8-P2) who presented with chilblains lesions and 
Figure 5. Ratios of 3-gene score (CXCL10 + GBP1 + SOCS1) over 25-gene score (3:25 gene ratio). (A) A ratio between 3 IFN-response genes with NF-κB 
transcription binding sites (CXCL10, GBP1, and SOCS1) and the 25 IFN genes with no NF-κB binding sites (3:25 ratio) was calculated. Depicted in the graph 
are the statistical significances (nonparametric Kruskal-Wallis test) from the comparisons of each group with CANDLE and SAVI patients combined: 
healthy controls (HC) and NOMID combined P < 0.0001, G1 P = 0.0017, G2 P = 0.0003, G3 P < 0.0001, G4 P = 0.0027, G5 P = 0.9271, G6 P = 0.6055, G7 P = 
0.1499, G8 P = 0.8684, G9 P = 0.0083, Non-IFN P < 0.0001. NS, not significant. Bars and error lines indicate median and interquartile range, respectively. 
Red shaded area indicates a high 3:25 gene ratio, blue shaded area indicates low ratio, and white area indicates normal ratio. Cutoffs were calculated in 
panel B. For the control groups (HC and NOMID) the same symbol is used for different individuals, as only one sample per patient is included. In all other 
groups, including CANDLE and SAVI, each patient is represented by a different symbol. (B) Two receiver operating characteristic (ROC) curves for the 3:25 
gene ratio to distinguish HC and NOMID from patients with NDAS (G3) and LRBA deficiency (G2) (ROC-1) and CANDLE and SAVI from HC and NOMID  
(ROC-2) are shown. A black arrow indicates the optimal cutoff (listed under each graph). AUC, area under the curve; SEN, sensitivity; SPE, specificity. The 
cutoffs for the ROC curves were marked in panel A with black arrows on the y axis. A list of genes in the IFN-gene score is published in ref. 34. *P < 0.05;  
**P < 0.01; ***P < 0.001; ****P < 0.0001.
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temic lupus erythematosus (SLE) and other JDM (Supplemental 
Figure 7). A ratio less than 0.07 or greater than 0.15 distinguished 
the canonical interferonopathies (SAVI or CANDLE) and patients 
with LRBA deficiency (G2) and with NEMO-NDAS (G3) from 
healthy controls and NOMID patients, respectively (Figure 5B). 
The 3:25 ratio was normal in IL-18PAP-MAS. Although most of 
the 28 IRGs assessed in the IFN score are strongly triggered by 
type I IFNs, 9 genes are also significantly activated by type II IFN 
(IFN-γ). Interestingly, a ratio of IFN-γ– and IFN-α– regulated genes 
over all genes was higher in the IL-18PAP-MAS than in CANDLE 
and SAVI (Supplemental Figure 6B).
Preliminary outcomes in patients who received treatment with 
a JAK inhibitor. Although this study was not conducted to col-
lect treatment outcomes, we report preliminary observations to 
increase available data on these very rare diseases to improve 
management (Supplemental Table 8). A total of 15 patients 
have received treatment with JAK inhibitors. Five patients 
received baricitinib in the context of a compassionate-use study 
(NCT01724580), and the other 10 patients received a JAK inhib-
itor through commercial sources: 7 received tofacitinib, 2 rux-
olitinib, and 1 baricitinib (Supplemental Table 8). Two patients 
expired during the period of this study. One patient had anti-
MDA5–antibody JDM and received ruxolitinib while on a venti-
lator for worsening lung disease. The other patient, a CANDLE 
patient, had severe primary pulmonary hypertension before start-
ing tofacitinib (30). One patient with a psoriasiform dermatitis 
and scarring skin fibrosis had no response to 9 months of treat-
ment and discontinued baricitinib treatment (G9-P1). Two addi-
tional CANDLE patients (G7-P5 and G7-P6) (28) and 1 patient with 
CANDLE-like disease and a somatic TREX1 mutation (G7-P3) had 
complete responses to JAK inhibition and continue on treatment. 
One patient with AGS5 (G5-P1) was previously reported (33) and 
has stable disease on baricitinib. Two patients with AGS-like dis-
ease had partial to minimal responses to baricitinib and tofacitinib 
(G5-P3 and G5-P4), respectively, with ongoing significant steroid 
requirement in 1 patient (G5-P3). Another patient with anti-MDA5 
antibody–positive JDM (G6-P1) had a partial response to low dose 
of tofacitinib with progressive soft tissue and cardiac calcifica-
tions. Of the patients in G1–G4 who were treated with a JAK inhib-
itor, the patient with IL-18PAP-MAS had a partial response with 
no progression of lung disease and decreasing serum IL-18 levels 
(G1-P7), and the patient with LRBA deficiency has had partial 
responses with resolving cytopenias and rashes, and lower steroid 
requirements (G2-P1). One patient with NEMO-NDAS (G3-P4) 
had a suboptimal response and discontinued tofacitinib. Final-
ly, 1 patient with SAMD9L-SAAD (G4-P1) had a partial response 
with ongoing skin disease and steroid requirements. Based on our 
findings, we suggest disease criteria to diagnose patients with and 
without an elevated IRG-S (Supplemental Table 9).
Discussion
Mendelian autoinflammatory interferonopathies present with 
chronic elevation of an IRG-S (summarized in ref. 34). Clinical 
benefit in patients treated with JAK inhibitors who have CAN-
DLE (11), SAVI (11, 35, 36), or AGS (37, 38) are encouraging, and 
the correlation of treatment responses with suppression of the 
IRG-S (34) suggests that the IRG-S is useful in diagnosis and as 
tial leveraging of the diversity in IRG regulation for diagnostic purposes. 
Though all disease groups had elevated IRG-S compared with neg-
ative controls (healthy controls and NOMID), the mean IRG-S ele-
vation was significantly lower in patients with IL-18PAP-MAS (G1), 
LRBA deficiency (G2), NEMO-NDAS (G3), and SAMD9L-SAAD 
(G4). Normalized gene expression for 25 of the 28 IRGs in our 
assay was significantly higher in CANDLE, SAVI, and disease 
groups G5–G8 compared with groups G1–G4 except for normal-
ized gene expression in 3 genes, CXCL10, GBP1, and SOCS1, which 
was equal or higher in groups G1–G4 compared with CANDLE and 
SAVI (Supplemental Figure 2 and Supplemental Figure 3A).
We hypothesized that the differential expression of these 
genes may be due to regulation by different transcription factors 
(TFs). We therefore assessed TF binding sites (TFBSs) in the 28 
genes in our IFN score. As expected, all 28 genes have TFBSs 
for STAT1 and other TFs activated by type-I IFNs. The 3 genes 
with relatively high expression compared with CANDLE and 
SAVI in patient groups G1–G4 have additional TFBSs for NF-κB1 
(CXCL10, GBP1, and SOCS1) and/or NF-κB2 (CXCL10) (Supple-
mental Figure 3B), thus suggesting that NF-κB–dependent acti-
vation of these IRGs may be relatively high in patients in G1–G4 
compared with STAT1-dependent activation, which differs in 
patients with CANDLE and SAVI. To validate a role of NF-κB in 
driving their expression, we used whole blood RNA-seq data to 
correlate the expression level of the 3 genes (CXCL10, GBP1, and 
SOCS1) with that of 11 genes that have NF-κB but no STAT1 TFBSs, 
by calculating summary Z scores, a “3-gene NF-κB/STAT1 score,” 
and an “11-gene NF-κB–only validation score” (Supplemental 
Methods and Supplemental Figures 3 and 4). The 3-gene NF-κB/
STAT1 score did not correlate with the 11-gene NF-κB–only valida-
tion score in healthy controls who have no IFN score elevation nor 
in CANDLE, and SAVI, where we expected predominant type-I 
IFN/STAT1 inflammation. However, the 11-gene NF-κB–only vali-
dation score highly correlated with the 3-gene NF-κB/STAT1 score 
in patients with LRBA deficiency (G2, r = 0.82, P = 0.02), NEMO-
NDAS (G3, r = 0.72, P = 0.03), and SAMD9L-SAAD (G4, r = 0.99, P 
= 0.002) (Supplemental Figure 5). A “25-gene STAT1-only score” 
of genes expressing only STAT1 but no NF-κB TFBSs did not cor-
relate with the 11-gene NF-κB–only validation score in any disease 
group with elevated IRG-S. Interestingly, in the IL-18PAP-MAS 
patients, neither the 3-gene NF-κB/STAT1 score nor the 25-gene 
STAT1-only score correlated with the 11-gene NF-κB–only score 
(G1) (Supplemental Figure 5B). TFs that are activated by recombi-
nant IL-18 (including FOS, ATF2, JUN, and ATF3) (32) were pres-
ent in the regulatory domains of many of the IRGs in the 28-gene 
IRG-S (data not shown). In support of the notion that free IL-18 
may coregulate the expression of IRGs in patients with IL-18PAP-
MAS, we correlated total serum IL-18 levels, which correlates with 
free IL-18 levels (15), with the IRG-S and found that only serum 
levels of IL-18 but not IL-18BP and CXCL9 correlated weakly with 
the 28-gene IRG-S (r = 0.3, P = 0.06; Supplemental Figure 6A).
A ratio of the 3-gene NF-κB/STAT1 score and the 25-gene 
STAT1-only score (3:25 ratio) to reflect the relative contribution of 
NF-κB versus STAT1/IFN–mediated inflammation was very low in 
CANDLE, SAVI, AGS, AGS-like disease (G5), anti-MDA5 autoan-
tibody–positive JDM (G6), CANDLE/CANDLE-like disease (G7), 
and SAVI-like disease (G8) (Figure 5A) as well as in childhood sys-
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later in life with concomitant cerebellar atrophy and risk of myel-
odysplasia. Other somatic and selective germline SAMD9L muta-
tions can cause pediatric early-onset myelodysplastic syndrome 
(MDS) (43). The 6 patients reported here harbor potentially novel, 
de novo frameshift mutations that are in close proximity to each 
other. The mutations cause immune dysregulation characterized 
by nodular panniculitis similar to CANDLE/PRAAS, and early- 
onset interstitial lung disease in most patients (unlike CANDLE/
PRAAS), and severe infection-associated myelosuppression/cyto-
penias. Genetic reversion that is described in pancytopenia and 
ataxia syndrome (41) and in pediatric MDS (43) was also seen in 1 
patient before bone marrow transplant. The inflammatory disease 
manifestations suggest that these heterozygous SAMD9L frame-
shift mutations confer a gain of function through mechanisms that 
need to be further investigated. Furthermore, the positive out-
come of bone marrow transplantation in 2 of the 6 patients, and 
the high mortality in patients who have severe concomitant lung 
disease, point to the importance of distinguishing these patients 
from CANDLE by making the diagnosis of SAMD9L-SAAD early.
Eight patients uniformly presented with recurrent MAS-like 
episodes and developed PAP/lipoid pneumonia and clubbing of 
their distal phalanges. They were diagnosed clinically as having a 
previously unrecognized disease that is referred to as IL-18PAP-
MAS. These patients’ histological findings of PAP are distinct from 
the interstitial fibrosis of SAVI, and are not seen in patients with 
NLRC4-associated MAS despite comparably high serum IL-18 
levels (12, 15). Similarly, elevated IL-18 levels are also seen in some 
patients with sJIA and adult Still’s disease, and are now recognized 
as factors predisposing to the development of MAS (15, 17, 45–47). 
Some of these patients are included in a publication that highlights 
a larger spectrum of sJIA patients who develop a heterogeneous 
spectrum of lung diseases that include PAP and interstitial lung 
fibrosis and are referred to as sJIA-LD (48). Patients with IL-18PAP-
MAS share a cytokine signature linked to high expression of IL-18 
and originally described in NLRC4-MAS (12), which includes 
hematopoietic growth factors/cytokines like M-CSF, SCF, and 
IL-3. Interestingly, humanized mice with transgenic expression of 
human SCF, IL-3, and GM-CSF develop spontaneous MAS direct-
ly mediated by myeloid cells (49), raising questions whether IL-18 
promotes the production of these growth factors. These mecha-
nisms may synergize with the known function of the role of IL-18 
as IFN-γ–stimulating factor in infections and may provide further 
potential mechanisms by which IL-18 confers MAS susceptibility. 
The presence of PAP suggests alveolar macrophage dysfunction 
in clearing surfactant from the alveoli, as is seen in patients with 
genetic or autoimmune GM-CSF deficiency (50). Whether treat-
ment aimed at blocking IL-18, or IFN-γ signaling, or treatments 
aimed at modifying phagocytosis and processing of surfactant by 
alveolar macrophages are viable treatment strategies needs further 
exploration. Genetic analyses have so far not been conclusive in the 
IL-18PAP-MAS patients nor the other sJIA-LD patients (48).
Interestingly, the magnitude and pattern of the IRG elevation 
differed between these 4 conditions (LRBA deficiency, NEMO-
NDAS, SAMD9L-SAAD, and IL-18PAP-MAS) versus CANDLE 
and SAVI. The expression of 3 IRGs that contain both NF-κB 
and STAT1 TFBSs (CXCL10, GBP1, and SOCS1) correlated with 
IFN-independent NF-κB–induced gene expression in LRBA defi-
a biomarker in monitoring treatment responses. In this study, a 
strategy for screening patients with undifferentiated autoinflam-
matory diseases that included assessment of IRG-S, cytokine pro-
filing, clinical phenotyping, and genomics led to characterization 
of additional disease groups of patients with both chronic and 
temporary IRG-S elevations, and to the development of a ratio of 
differentially regulated IRGs that were included in a 28-gene score 
that distinguishes the additional conditions from the canonical 
interferonopathies, CANDLE, SAVI, and AGS.
Compared with patients with a negative IRG-S, which included 
patients with osteomyelitis, CAPS-like disease, periodic fever syn-
dromes, and sJIA-like disease with MAS flares and high IL-18 lev-
els, most of which responded to IL-1–blocking treatments, patients 
with elevated IRG-S had more severe disease and higher mortality, 
thus underlining the unmet need to find better treatments.
The characterization of patients with clinical phenotypes that 
resemble CANDLE/PRAAS, who had overall lower IRG-S and 
developed progressive B cell cytopenias and/or hypogammaglob-
ulinemia, led to the recognition of 3 distinct, monogenic condi-
tions that underline the importance of assessing these mutations 
in patients suspected to have CANDLE/PRAAS and who are neg-
ative for mutations in genes that encode proteasome components. 
Two patients with CANDLE/PRAAS-like phenotypes had loss-of-
function mutations in LRBA causing LRBA deficiency (39). Both 
patients (G2-P1 and G2-P2) had panniculitis and lower CTLA4 
surface expression on CD4+ T cells than controls (data not shown), 
which confirm that the mutations impact CTLA4 recycling (26). 
However, both patients carry other mutations that may affect 
IFN signaling (Supplemental Table 4). It therefore remains to be 
determined whether the IFN signature is a characteristic part of 
the immune dysregulation of patients with LRBA deficiency (22) 
or is associated with other rare variants in those patients. Patient 
G2-P1 is partially responding to JAK inhibition with concomitant 
decrease in IRG-S after previously unsatisfactory responses to 
sirolimus and abatacept (Supplemental Table 4), suggesting a pos-
sible pathogenic role of increased IFN signaling.
Four patients harbor potentially novel splice variants in 
IKBKG/NEMO, the gamma subunit of the IκB kinase complex 
that activates NF-κB. In contrast with patients deficient in the 
NEMO protein who exhibit immunodeficiency, patients with 
the NEMO spliced mutant who lack only exon 5 (NEMOΔexon5) 
do not present with severe immunodeficiency but with system-
ic inflammation panniculitis and elevated IRG-S. Hanson et al. 
recently explored the molecular mechanisms that coactivate 
NF-κB and IRGs in these patients and called the disease NEMO-
NDAS and found that NEMOΔexon5 stabilizes the TBK1/IKKi 
complex and facilitates IRF3 phosphorylation, IFNB1 transcrip-
tion, and concomitant NF-κB activation. These evaluations pro-
vide a potential mechanistic explanation for the type-I IFN–asso-
ciated “autoinflammatory” clinical features and the concomitant 
NF-κB nuclear translocation in this previously unrecognized 
inflammatory syndrome (40).
A severe perinatal-onset inflammatory disease was seen in 
6 patients with frameshift mutations in SAMD9L that is pheno-
typically distinct from 2 diseases previously associated with het-
erozygous missense mutations in SAMD9L (41–44). One of the 
diseases, pancytopenia and ataxia syndrome (41, 44), presents 
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their unaffected family members when available. Healthy controls 
were recruited through the same study, NCT02974595, and were 
siblings or family members who have no mutations. For some assays, 
anonymous healthy blood donors were used.
Clinical, immunological, and genetic evaluation
We assessed 57 patients at the NIH (including physical exam, clinically 
indicated imaging, and a chest CT) and immunologically (T, B, NK cell 
count, immunoglobulins, and rheumatologic work up). Five patients 
passed away before an NIH visit could be arranged, and in 4 patients 
logistical problems precluded travel to the NIH. Samples for genetic 
testing were obtained from all 66 patients either at the NIH or were 
sent under NCT02974595. WES was performed in 19 trios, 1 duo, 
and 4 singletons, whole-genome sequencing (WGS) in 36 trios and 1 
duo; 5 patients had Sanger sequencing of candidate genes performed 
only. Confirmatory targeted (Sanger) sequencing of candidate genes 
detected by WES or WGS was performed. Next-generation sequenc-
ing data are registered in NCBI’s dbGaP database (https://www.ncbi.
nlm.nih.gov/gap/) under accession number phs001946.v1.p1.
Cytokine analysis
Serum was collected from 53 of 66 patients and 5 healthy controls. 
Cytokine concentrations of 48 analytes were measured using the Bio-
Plex system (Bio-Rad) (3) in 2 batches. Cytokine analysis was done in 
28 of the 36 patients with elevated IFN signature (presumed undif-
ferentiated interferonopathy [UIFN]). The first batch included 45 
patients, 20 with UIFN and 25 without UIFN, and 5 healthy controls, 
and the second batch included 8 patients with an UIFN. Due to a ceil-
ing effect of high serum IL-18 levels in the Bio-Plex system, all sam-
ples with levels greater than 10,000 pg/mL were re-run in a dedicated 
ELISA assay, as previously described (15). All patients with a history 
of MAS had serum measurements that included IL-18, IL-18BP, and 
CXCL9 (MIG) as described in Weiss et al. (15).
NanoString 28-gene IRG-S
At least 1 IRG-S was obtained for 65 of 66 patients. It was not obtained 
from 1 patient with a SAMD9L mutation (G4-P5). As previously report-
ed, total RNA was extracted from blood samples collected in Paxgene 
tubes (Qiagen). Gene expression of selected IRGs was determined by 
NanoString (NanoString Technologies) and an IRG-S was calculated 
as previously described based on healthy control data (34).
Within the 28 IRGs of the NanoString IRG-S, 3 IRGs were identified 
as having an NFKB1 and/or an NFKB2 TFBS. For validation and correla-
tion of a 3-gene subscore of IRGs with STAT1 and NF-κB1 and NF-κB2 
TFBSs with other genes preferentially activated by NF-κB1 and NF-κB2 
that lack STAT1 binding sites, please refer to Supplemental Methods D, 
Supplemental Figure 3B, and Supplemental Figure 4, A and B.
Evaluation of the 3-gene to 25-gene ratio (3:25 ratio) in the various 
diseases. A ratio of the sum of the normalized counts of the 3 Nano-
String ISGs with NF-κB binding sites (CXCL10, GBP1, and SOCS1) and 
the sum of the normalized counts of the 25 other genes was generated 
and compared between diseases.
Statistics
Descriptive analyses were performed; no adjustments for multiple 
comparisons were made. For normally distributed data, parametric 
tests (unpaired 2-tailed t tests for group comparison, i.e., cytokine 
ciency and NEMO-NDAS, and in SAMD9L-SAAD during flares 
when IRG-S was elevated, suggesting a relatively large effect of 
NF-κB signaling, compared with the canonical interferonopa-
thies (CANDLE, SAVI, and AGS) and some autoimmune interfer-
onopathies. Although preliminary, our data suggest that patients 
with IL-18PAP-MAS, LRBA deficiency, NEMO-NDAS, and SAM-
D9L-SAAD may have more variable responses to JAK inhibition 
than CANDLE patients, consistent with the observation that the 
inflammatory response is complex. The partial response to JAK 
inhibition would be expected in this scenario and may suggest 
treatment combinations that target the IFN-mediated and NF-κB–
mediated dysregulation. In the IL-18PAP-MAS patients, IRGs 
induced by IFN-α and IFN-γ relative to those induced by predom-
inantly IFN-α were higher in IL-18PAP-MAS than in the other dis-
eases. The pattern of IRGs did not correlate with NF-κB–induced 
genes, but correlated weakly with the patients’ highly elevated 
total serum IL-18 levels (often >200,000 pg/mL, whereas normal 
levels are <500 pg/mL) (15). As any of the IRGs in the 28-gene 
IRG-S have TFs in their respective regulatory domains that are 
activated by recombinant IL-18, the correlation of IL-18 levels with 
the IRG-S suggests that free IL-18 may coregulate the expression 
of IRGs in patients with IL-18PAP-MAS. IL-18 induces IFN-γ (51), 
which emerges as a critical downstream mediator of the patho-
genesis of MAS (15). Whether and how free IL-18 drives the IRG-S, 
directly via coregulating expression of IRGs or via promoting 
IFN-γ needs to be evaluated. Pathomechanisms underlying the 
promising results with JAK inhibition in MAS and hemophago-
cytic lymphohistiocytosis (52–54) may be partially attributable to 
IFN-γ receptor signaling blockade (21), but treatments targeting 
the IL-18/IFN-γ axis are promising (55).
Overall, this study establishes the value of screening for an 
interferon signature and for high serum IL-18 levels and expands 
the diagnostic armamentarium that supports the challenging 
evaluation of patients with undifferentiated autoinflammato-
ry diseases. The diagnosis of IL-18PAP-MAS, NEMO-NDAS, 
SAMD9L-SAAD, and LRBA deficiency needs to be considered in 
patients presenting with elevated IRG-S and clinically suggestive 
features. A high ratio of 3:25 differentially regulated IRGs identified 
NEMO-NDAS, LRBA deficiency, and a normal ratio was seen in the 
SAMD9L-SAAD patients. These diseases mimic CANDLE/PRAAS 
clinically but higher 3:25 ratios suggest a relatively increased NF-κB 
signaling distinct from CANDLE/PRAAS and SAVI. Future investi-
gations are necessary to determine whether the 3:25 ratio will be 
useful in predicting response to IFN-targeted monotherapy, versus 
the need for additional treatments.
Methods
Patients and healthy controls
Between 2014 and 2017, 66 consecutive patients with pre-
sumed undifferentiated autoinflammatory diseases who had no 
genetic diagnosis upon referral were included in an institution-
al review board–approved (IRB-approved) natural history study 
(NCT02974595). All clinical investigations were conducted accord-
ing to Declaration of Helsinki principles. Written informed consent 
was obtained from the subjects or their parents either at the NIH or 
by phone consent. Blood samples were collected from patients and 
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and acquired and analyzed data. SC acquired and analyzed clinical 
and biomarker subspecialty data. AJO oversaw the statistical anal-
yses of the study data. YH and GAMS acquired clinical data. KRC 
interpreted clinical and bone marrow biopsy data. SB and ZD ana-
lyzed genetic data. AAJ and RGM designed the study, analyzed the 
data, and wrote the first draft of the manuscript. Authors listed in 
the Autoinflammatory Disease Consortium (AA to TWM) provid-
ed critical patient information and phenotyping data. All authors 
reviewed and approved the final version of the manuscript.
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